Lucid Diagnostics to Host Investor Call on Monday, September 8, 2025

Conference call scheduled for Monday, September 8, at 8:30 AM ET to discuss September 4 MolDX Contractor Advisory Committee (CAC) meeting

NEW YORK, Sept. 5, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM) ("PAVmed"), today announced it will host a conference call on Monday, September 8, 2025, at 8:30 a.m. Eastern Time to discuss the September 4 Contractor Advisory Committee ("CAC") Meeting convened by MolDX-participating Medicare Administrative Contractors as part of the reconsideration of Local Coverage Determination (LCD) L39256, "MolDX: Molecular Testing for Detection of Upper Gastrointestinal Metaplasia, Dysplasia, Neoplasia," for Lucid's EsoGuard^® Esophageal DNA Test.

Read more at prnewswire.com